A share price of Heron Therapeutics Inc [HRTX] is currently trading at $1.49, up 7.19%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The HRTX shares have gain 20.16% over the last week, with a monthly amount glided 8.76%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Heron Therapeutics Inc [NASDAQ: HRTX] stock has seen the most recent analyst activity on June 09, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $6. Previously, Rodman & Renshaw started tracking the stock with Buy rating on June 13, 2024, and set its price target to $7. On April 23, 2024, CapitalOne initiated with an Overweight rating and assigned a price target of $6 on the stock. Needham reiterated its Buy rating and increased its price target to $5 on March 13, 2024. Guggenheim initiated its recommendation with a Buy and recommended $24 as its price target on May 27, 2020. Needham reiterated a Buy rating for this stock on February 20, 2020, and downed its price target to $48. In a note dated January 16, 2019, Needham reiterated a Buy rating on this stock and revised its target price from $66 to $64.
Heron Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.00 and $2.68. Currently, Wall Street analysts expect the stock to reach $6.67 within the next 12 months. Heron Therapeutics Inc [NASDAQ: HRTX] shares were valued at $1.49 at the most recent close of the market. An investor can expect a potential return of 347.65% based on the average HRTX price forecast.
Analyzing the HRTX fundamentals
Trailing Twelve Months sales for Heron Therapeutics Inc [NASDAQ:HRTX] were 155.10M which represents 16.47% growth. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at 0.01%, Pretax Profit Margin comes in at -0.09%, and Net Profit Margin reading is -0.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is 0.73 and Total Capital is 0.01. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 9.44.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Heron Therapeutics Inc [NASDAQ:HRTX] is 2.56. Also, the Quick Ratio is 1.78, while the Cash Ratio stands at 0.48. Considering the valuation of this stock, the price to sales ratio is 1.76, the price to book ratio is 38.89.
Transactions by insiders
Recent insider trading involved Rubric Capital Management LP, 10% Owner, that happened on Aug 08 ’25 when 2.39 million shares were purchased. Director, Morgan Adam completed a deal on Aug 08 ’25 to buy 1.77 million shares.
